A simple protein-based surrogate neutralization assay for SARS-CoV-2

• DOI: 10.1172/jci.insight.142362
• Publication Date: 2020-09-01T18:51:53Z
• Authors: Kento T. Abe; Zhijie Li; Reuben Samson; Payman Samavarchi...; Emelissa J. Valcourt; Heidi Wood; Patrick Budylowski; Alan P. Dupuis; Roxie C. Girardin; Bhavisha Rathod; Jenny H. Wang; Miriam Barrios-Ro...; Karen Colwill; Allison J. McGeer; Samira Mubareka; Jennifer L. Gomme...; Yves Durocher; Mario Ostrowski; Kathleen A. McDon...; Michael A. Drebot; Steven J. Drews; James M. Rini; Anne-Claude Gingras
• Keywords: Coronavirus

Most of the patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mount a humoral immune response to virus within few weeks infection, but duration this and how it correlates clinical outcomes has not been completely characterized. Of particular importance is identification infection that would support public health decision-making on treatment approaches, vaccination strategies, convalescent plasma therapy. While ELISA-based assays detect quantitate antibodies SARS-CoV-2 in patient samples have developed, detection neutralizing typically requires more demanding cell-based viral assays. Here, we present safe efficient protein-based assay for serum block interaction spike protein receptor binding domain (RBD) its receptor, angiotensin-converting enzyme (ACE2). The serves as surrogate neutralization performed same platform parallel an ELISA against RBD, enabling direct comparison. results obtained our correlate those viral-based assays, plaque reduction test (PRNT) uses live pseudotyped vector–based assay.